Table 1 Summarised characteristics of reviewed studies.
Total | 25 studies |
|---|---|
Year of publication | 1995–2020 |
Total patients (range) | 3326 (22–420) |
Sequencing technique | |
Sanger | 17 |
Next-generation | 7 |
Pyrosequencing | 1 |
Anatomical subsite | |
Mixed | 9 studies (1957 patients) |
Oral | 8 studies (994 patients) |
Larynx | 5 studies (238 patients) |
Oropharynx | 1 study (68 patients) |
Sinonasal | 1 study (57 patients) |
Nasopharyngeal | 1 study (22 patients) |
Outcome measures | |
Overall survival | 21 studies |
Disease free survival | 14 studies |
Disease specific survival | 3 studies |
Geographical region | |
Europe | 12 studies, 7 countries: Italy, Netherlands, Serbia, Germany, Denmark, Sweden, France |
North America | 6 studies, 2 countries: USA, Canada |
Asia | 6 studies, 3 countries: Japan, China, Taiwan |
Oceania | 1 study, 1 country: Australia |
